Category: Politics & Business

Medtronic Minimed Revel

UnitedHealthcare, We Need Insulin Pump Choices

In its May bulletin to healthcare providers, UnitedHealthcare (@myUHC) announced that, starting July 1st 2016, Medtronic would be its “preferred” in-network provider of insulin pumps for its adult customers with Type 1 diabetes. This means that, with a few exceptions, if you’ve got Type 1 diabetes and health insurance from United, your next pump is going to be Medtronic. And since United is the nation’s largest insurance company, it’s conceivable that other insurance companies will follow suit.
0 Shares
Insulin for Syrians withe Diabetes

Insulin Desperately Needed for Syrians With Diabetes

T1International works alongside people with diabetes around the world to advocate for access to diabetes supplies. The charity is currently running their Insulin for Syrians campaign, encouraging people to donate money that will be used to provide insulin and diabetes supplies to families in Aleppo and other locations in Syria where aid has been cut off.
0 Shares
The Hugely Inflated Prices of Glumetza and Metformin ER

The Hugely Inflated Prices of Glumetza and Metformin ER

I may have been very late to the astonishing price increase of Glumetza, but I am, by coincidence, among the first to report that the generic price is almost as ridiculous. My bill, $14,009.23, was for the generic, available, as promised, in February 2016 and manufactured by Lupin, an Indian pharmaceutical company that is the sixth largest maker of generics in the world.
0 Shares
JDRF New Logo

JDRF and Tidepool Partner to Bring Data to an Open Source Platform for People with Type 1 Diabetes

JDRF, the leading research and advocacy organization funding type 1 diabetes (T1D) research, and Tidepool, a Silicon Valley-based non-profit organization committed to reducing the burden of T1D, announced a partnership supported by JDRF funding for data access technology for people with T1D who use insulin pumps and continuous glucose monitors (CGMs) through a device agnostic cloud platform.
0 Shares
Novo Nordisk Logo

Novo Nordisk To Focus On Diabetes, Not Inflammatory Disorders

Novo Nordisk has decided to discontinue all its research and development (R&D) activities within inflammatory disorders while increasing efforts within diabetes prevention and treatment, obesity and diabetes complications. The decision to discontinue all R&D within inflammatory disorders follows a review of Novo Nordisk's strategic position in the therapeutic area after...
0 Shares